Icotyde (icotrokinra)
Janssen Biotech (Johnson & Johnson) (JNJ)
ApprovedMar 17, 2026
Marketer take
An oral IL-23 receptor-blocking peptide for moderate-to-severe psoriasis in patients 12 and older, which challenges injectable IL-23 and IL-17 biologics and Sotyktu on convenience with dermatologists and payers.
- Sponsor company
- Janssen Biotech (Johnson & Johnson) (JNJ)
- Indication
- To treat moderate-to-severe plaque psoriasis in patients 12 years and older who weigh at least 40 kg and who are candidates for systemic therapy or phototherapy
- Therapeutic area
- Immunology, Dermatology
- Event
- FDA approval
- Date
- Mar 17, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?